AbbVie: Schizophrenia trials

The registry lists 27 Schizophrenia studies with AbbVie as lead sponsor. 1 are open to participants now and 11 have results posted.

Phase 1 6Phase 2 13Phase 3 8(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With SchizophreniaRecruitingNCT07145918Phase 2
• A Study to Evaluate Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With SchizophreniaTerminatedNCT05443724Phase 2Results posted
• Study to Assess Adverse Events and Change in Disease Activity of Oral Cariprazine Capsules in Adult Participants With SchizophreniaTerminatedNCT05368558Phase 3Results posted
• A Trial of 15 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With SchizophreniaCompletedNCT05227703Phase 2Results posted
• A Trial of 10 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With SchizophreniaCompletedNCT05227690Phase 2Results posted
• Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in a Dose-Reduction Paradigm in the Prevention of Relapse in Participants With SchizophreniaTerminatedNCT03593213Phase 3Results posted
• A Study of Cariprazine in the Prevention of Relapse of Symptoms in Participants With SchizophreniaCompletedNCT01412060Phase 3Results posted
• Long-term Study of Cariprazine in Patients With SchizophreniaCompletedNCT01104792Phase 3Results posted
• Safety and Efficacy of Cariprazine in SchizophreniaCompletedNCT01104779Phase 3Results posted
• Safety and Efficacy of Cariprazine in Patients With SchizophreniaCompletedNCT01104766Phase 3Results posted
• A Study of Cariprazine in Patients With Chronic Stable SchizophreniaCompletedNCT00839852Phase 2Results posted
• Safety and Efficacy of Cariprazine (RGH-188) in the Acute Exacerbation of SchizophreniaCompletedNCT00694707Phase 2Results posted
• Trial to Study the Effect of CVL-231 on 24-Hour Ambulatory Blood Pressure in Participants With SchizophreniaCompletedNCT05245539Phase 1
• Pharmacokinetics of CVL-231 Following Single Oral Administration of Modified- and Immediate-release Formulations in Fasted and Fed Healthy ParticipantsCompletedNCT05106309Phase 1
• PET Trial to Evaluate Target Occupancy of CVL-231 on Brain Receptors Following Oral DosingCompletedNCT04787302Phase 1
• Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum DisorderCompletedNCT04578756Phase 3
• A Multiple Ascending Dose Trial of CVL-231 in Subjects With SchizophreniaCompletedNCT04136873Phase 1
• Long-term Safety and Efficacy of ABT-126 in Subjects With Schizophrenia: An Extension Study for Subjects Completing Study M10-855 (NCT01655680)TerminatedNCT01834638Phase 2
• A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in SchizophreniaCompletedNCT01678755Phase 2
• A Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in SchizophreniaCompletedNCT01655680Phase 2
• Long-Term Safety Extension Trial of Asenapine in Schizophrenia Participants Who Completed Protocol P05688 (P05689)CompletedNCT01617200Phase 3
• Effects of Cariprazine on Cardiac Repolarization in Patients With SchizophreniaCompletedNCT01376076Phase 1
• Safety and Efficacy Study for Cognitive Deficits in Adult Subjects With SchizophreniaCompletedNCT01095562Phase 2
• Efficacy and Safety Study for Cognitive Deficits in Adult Subjects With SchizophreniaCompletedNCT01077700Phase 2
• A Multiple Dose Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ABT-288 in Stable Subjects With SchizophreniaCompletedNCT00888693Phase 1
• Study Evaluating RGH-188 in the Treatment of Patients With SchizophreniaCompletedNCT00404573Phase 2
• Evaluation of the Safety and Efficacy of Memantine as Adjunctive Treatment in Schizophrenia PatientsCompletedNCT00097942Phase 2